切换至 "中华医学电子期刊资源库"
高级检索
中华消化病与影像杂志(电子版)

中华消化病与影像杂志(电子版) ›› 2024, Vol. 14 ›› Issue (03) : 268 -274. doi: 10.3877/cma.j.issn.2095-2015.2024.03.017

综述

幽门螺杆菌阴性胃黏膜相关淋巴组织淋巴瘤的研究进展
安亚楠1, 王端然1, 郭甜甜1, 武希润1,†()   
  1. 1. 030001　太原，山西医科大学第二临床医学院
  • 收稿日期:2023-11-12 出版日期:2024-06-01
  • 通信作者: 武希润

Research progress of Helicobacter pylori negative gastric mucosa-associated lymphoid tissue lymphoma

Yanan An1, Duanran Wang1, Tiantian Guo1, Xirun Wu1,†()   

  1. 1. Second Clinical Medical School, Shanxi Medical University, Taiyuan 030001, China
  • Received:2023-11-12 Published:2024-06-01
  • Corresponding author: Xirun Wu
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

安亚楠, 王端然, 郭甜甜, 武希润. 幽门螺杆菌阴性胃黏膜相关淋巴组织淋巴瘤的研究进展[J]. 中华消化病与影像杂志(电子版), 2024, 14(03): 268-274.

Yanan An, Duanran Wang, Tiantian Guo, Xirun Wu. Research progress of Helicobacter pylori negative gastric mucosa-associated lymphoid tissue lymphoma[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(03): 268-274.

随着医疗技术的发展，越来越多的证据表明，胃黏膜相关淋巴组织（MALT）淋巴瘤的发生与幽门螺杆菌（Hp）的感染密切相关。通过单纯根除Hp治疗已成为该疾病的一线治疗方案。但目前发现，还有绝大部分胃MALT淋巴瘤患者不存在Hp感染，Hp阴性的胃MALT淋巴瘤的发病机制、内镜临床表现和治疗方式与阳性患者存在不同。且治疗方案存在争议。本文总结了Hp为阴性的胃MALT淋巴瘤的发病机制、临床表现及治疗方案，并对未来治疗进行展望，为提高该疾病的治愈率以及降低不良反应发生率提供参考。

关键词: 胃黏膜相关淋巴组织淋巴瘤, 螺杆菌，幽门, 发病机制, 诊断与治疗, 预后

With the development of medical technology, more and more evidence shows that the occurrence of gastric mucosa-associated lymphoid tissue (MALT) lymphoma is closely related to the infection of Helicobacter pylori (Hp). Treatment by simple eradication of Hp has become the first-line treatment for the disease. However, it has been found that most patients with gastric MALT lymphoma do not have Hp infection, and the pathogenesis, endoscopic clinical manifestations and treatment methods of HP-negative gastric MALT lymphoma are different from those of positive patients. And treatment options are controversial. In this paper, the pathogenesis, clinical manifestations and treatment of HP-negative gastric MALT lymphoma are summarized, and the future treatment is prospected, so as to provide reference for improving the cure rate of this disease and reducing the incidence of adverse reactions.

Key words: Gastric mucosa-associated lymphoid tissue lymphoma, Helicobacter pylori, Pathogenesis, Diagnosis and treatment, Prognosis
表1 存在基因突变的文献
文献信息 病例总数 基因突变统计
总数 Hp阴性 Hp阳性
Jung H 2023[5] 22 6 6 0
Liu H 2001[8] 21 9 9 0
Hiroshi Inagaki 2004[9] 115 21 11 10
Lévy M 2005[10] 53 17 12 5
Raderer M 2005[11] 6 1 1 0
Wundisch T2005[12] 65 10 10 0
Nakamura S 2006[13] 54 7 6 1
Taiji Akamatsu 2006[14] 14 6 3 3
Nakamura T 2008[15] 87 15 8 7
Wang G 2009[16] 48 15 NA NA
Asano N 2012[17] 18 7 7 0
Nakamura S 2012[18] 206 30 NA NA
Choi YJ 2013[19] 66 10 5 5
Raderer M 2015[20] 97 3 3 0
Strati P 2019[21] 26 3 3 0
Kim SH 2023[22] 2 2 2 0
Takigawa H 2021[38] 182 13 5 8
Takigawa H 2023[42] 137 17 14 3
汇总 1219 192 105 42
图1 溃疡合并结节型病变，主要分布于胃窦部且病变多发
图2 窄带成像放大内镜染色可见血管形态呈现树样外观
表2 Hp阴性胃MALT淋巴瘤内镜特点
文献信息 例数 年龄(岁) 病灶数目(单个/多个) 发病部位(近端/远端) 病变性质(浅表型/溃疡型/结节型) 浸润深度(黏膜及黏膜下层/肌层及以下) 分期(早期/进展期)
Nakamura S 2006[13] 10 58(41~80) NA 7/3 溃疡/其他类型4/6 3/7 7/3
Taiji Akamatsu 2006[14] 16 64.8(39~80) 12/4 10/2(4例弥漫) 0/16/0 14/2 14/2
Asano N 2012[17] 18 58.5 3/15 2/16 14/0/4 NA 18/0
Choi YJ 2013[19] 13 60.23 11/2 5/8 10/3/0 4/9 9/4
Park HS 2010[29] 11 55.7(36~73) 5/6 2/3(6例弥漫) 溃疡/结节6/3(2例混合) NA NA
Ryu KD 2014[30] 14 57 5/9 3/2(9例弥漫) 12/2/0 NA 10/4
Gong EJ 2016[31] 28 52(48~59) NA 12/16 20/8/0 27/1 25/3
Kim JS 2016[32] 12 58.5 2/10 4/2(6例弥漫) 9/3/0 NA 9/3
柳娟2019[33] 13 52(46~65) 3/10 6/1(6例弥漫) NA NA 4/9
汇总 135   41/56 51/53(31例弥漫) 浅表型65；溃疡型27；结节型7；其他8 48/19 96/28
表3 不同类型Hp阴性胃MALT淋巴瘤患者疗效对比
  无基因突变 存在基因突变
治疗方式 抗Hp治疗 抗Hp治疗 放射治疗
有效率 36.22% 8.77% 33.33%
表4 Hp阴性胃MALT淋巴瘤患者不同治疗措施疗效及随访观察
文献 例数 Hp阴性(例) 抗Hp治疗(例) 无基因改变 存在基因改变 基因改变(例) 联合其他治疗措施 随访时间 随访结局
抗Hp治疗 抗Hp治疗 放疗 治疗无效
Jung H 2023[5] 65 22 5 3/7CR 6 1 5 0 无 NA NA
Kuo SH 2017[6] 25 25 25 9/25CR 7 0 NA 7 12例无反应患者追加化疗 51(34.7~67.3)个月 无复发及转移
Taiji Akamatsu 2006[14] 57 16 9 1/9CR 3 0 0 3 无 48个月 无复发及转移
Nakamura T 2008[15] 86 16 17 1/17CR 8 1 5 2 NA 9.5(2.5~17)年 无复发及转移
Asano N 2012[17] 158 18 17 5/11CR 7 1 2 4 无 7年 无复发及转移
Nakamura S 2012[18] 420 44 44 6/44CR NA NA NA NA 无 6.5(3~14.6)年 无复发及转移
Choi YJ 2013[19] 66 13 5 2/5CR、1/5PR、2/5SD 7 0 NA 7 无 26~35个月 无复发及转移，SD患者无进展
Raderer M 2015[20] 97 24 13 5 /13CR、1/13PR、4/13SD、3/13PD 3 1(PR) 0 2 SD患者追加化疗 95(42~181)个月 2例CR分别于19、23个月后复发，1PR26个月后进展
Strati P2019[21] 64 26 26 10/26CR NA NA NA NA SD患者放疗后达CR 11年 2例复发
Kim SH 2023[22] 2 2 0 0 2 0 2 0 无 NA NA
Park HS 2010[29] 11 11 3 3/3CR NA NA NA NA 无 25(5~76)个月 无复发及转移
Gong EJ 2016[31] 345 28 28 16/28CR NA NA NA NA 7例追加放化疗 11.5 (6.2~16.8)个月 1例CR9个月后复发
Kim JS 2016[32] 54 12 6 3/6CR，2/6SD，1/6PD NA NA NA NA SD患者追加化疗 13(6~27)个月 1例17个月后复发
柳娟2019[33] 44 13 4 3/4CR，1/4SD NA NA NA NA SD患者追加化疗后达CR 8.1(5~10)个月 1例CR8个月后复发
Lu SN 2022[37] 1 1 1 1 NA NA NA NA NA 5个月 NA
Takigawa2021[38] 182 34 29 15/29CR 13 0 5 8 无 NA NA
Moleiro J 2016[39] 144 12 12 5/12CR NA NA NA NA 无 7(2~63)个月 无复发及转移
Li XW 2016[40] 73 4 4 2/4CR NA NA NA NA 无 62.9(1~226)个月 NA
Angelo Zullo[41] 110 110 110 11/110CR NA NA NA NA 无 14~48个月 1例14个月后复发
Stathis A 2009[43] 105 14 14 5/14CR NA NA NA NA NA 6.3年 3例复发
汇总 2115 451 312 110CR，3PR，10SD，4PD 57 4CR，1PR 19CR 33     12例复发，1例进展
[1]
Gu SX, Siddon AJ, Huntington SF, et al. Helicobacter pylori–negative mucosa-associated lymphoid tissue(MALT) lymphoma of the stomach: A clinicopathologic analysis [J]. Am J Clin Pathol, 2023, 160(6): 612-619.
[2]
解雅淋 何春燕, 韦思琪, 等. 幽门螺杆菌根除治疗对幽门螺杆菌阴性胃MALT淋巴瘤疗效的研究进展 [J]. 胃肠病学和肝病学杂志, 2020, 29(12): 1416-1419, 1424.
[3]
Taillieu E C K, Amorim I, Gärtner F, et al. Gastric Helicobacter species associated with dogs, cats and pigs: significance for public and animal health [J]. Vet Res, 2022, 53(1): 42.
[4]
Rodríguez-Sevilla J J, Salar Antonio. Recent Advances in the Genetic of MALT Lymphomas [J]. Cancers(Basel), 2021, 14(1): 176.
[5]
Jung H, Shin D W, Cheung D Y, et al. [Clinical Impact Assessment and Utilization Prospects of the t(11: 18) Chromosomal Translocation in Gastric MALT Lymphoma in Koreans: A Single Center Retrospective Analysis [J]. KJG, 2023, 81(1): 29-35.
[6]
Kuo S H, Yeh K H, Wu M S, et al. First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma [J]. Sci Rep, 2017, 7(1): 14333.
[7]
Toyoda K, Maeshima A M, Nomoto J, et al. Mucosa-associated lymphoid tissue lymphoma with t(11;18)(q21;q21) translocation: long-term follow-up results [J]. Ann Hematol, 2019, 98(7): 1675-1687.
[8]
Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy [J]. Lancet, 2001, 357(9249): 39-40.
[9]
Hiroshi Inagaki T N, Li Chunmei, Sugiyama Toshiro, et al. Gastric MALT Lymphomas Are Divided Into Three Group Based on Responsiveness to Helicobacter Pylori Eradication and Detection of API2-MALT1 Fusion [J]. Am J Surg Pathol, 2004, 28(12): 1560-1567.
[10]
Lévy M, Copie-Bergman C, Gameiro C, et al. Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy [J]. J Clin Oncol, 2005, 23(22): 5061-5066.
[11]
Raderer M, Streubel B, Wohrer S, et al. Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas [J]. Gut, 2005, 55(5): 616-618.
[12]
Wundisch T, Thiede C, Morgner A, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication [J]. J Clin Oncol, 2005, 23(31): 8018-8024.
[13]
Nakamura S, Matsumoto T, Ye H, et al. Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: a clinicopathologic and molecular study with reference to antibiotic treatment [J]. Cancer, 2006, 107(12): 2770-2778.
[14]
Taiji Akamatsu T M, Okiyama Yoko, Matsumoto Akihiro, Miyabayashi Hideharu, et al. Comparison of localized gastric mucosa-associated lymphoid tissue(MALT) lymphoma with and without Helicobacter pylori infection [J]. Helicobacter, 2006, 11(2): 86-95.
[15]
Nakamura T, Seto M, Tajika M, et al. Clinical features and prognosis of gastric MALT lymphoma with special reference to responsiveness to H. pylori eradication and API2-MALT1 status [J]. Am J Gastroenterol, 2008, 103(1): 62-70.
[16]
Wang G, Auerbach A, Wei M, et al. t(11;18)(q21;q21) in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in stomach: a study of 48 cases [J]. Mod Pathol, 2009, 22(1): 79-86.
[17]
Asano N, Iijima K, Terai S, et al. Eradication therapy is effective for Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma [J]. Tohoku J Exp Med, 2012, 228(3): 223-227.
[18]
Nakamura S, Sugiyama T, Matsumoto T, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan [J]. Gut, 2012, 61(4): 507-513.
[19]
Choi Y J, Kim N, Paik J H, et al. Characteristics of Helicobacter pylori-positive and Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma and their influence on clinical outcome [J]. Helicobacter, 2013, 18(3): 197-205.
[20]
Raderer M, Wohrer S, Kiesewetter B, et al. Antibiotic treatment as sole management of Helicobacter pylori-negative gastric MALT lymphoma: a single center experience with prolonged follow-up [J]. Ann Hematol, 2015, 94(6): 969-973.
[21]
Strati P, Lee S T, Teegavarupu P, et al. Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma [J]. Am J Hematol, 2019, 94(6): E150-E153.
[22]
Kim S H, Soliman Y, Chitnavis V N, et al. Helicobacter Pylori-Negative MALT Lymphoma: A Series of Two Cases Presenting with Life-Threatening Upper Gastrointestinal Bleeding [J]. Case Rep Gastrointest Med, 2023, 2023: 8244696.
[23]
Raderer M, Kiesewetter B, andDu M Q. Clinical relevance of molecular aspects in extranodal marginal zone lymphoma: a critical appraisal [J]. Ther Adv Med Oncol, 2023, 15: 17588359231183565.
[24]
Ye Hongtao, Gong Liping, Liu Hongxiang, et al. MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression. [J]. J. Pathol, 2005, 205(3): 293–301.
[25]
Raderer M, Kiesewetter B, Ferreri AJ. Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue(MALT lymphoma) [J]. CA Cancer J Clin, 2016, 66(2): 153-171.
[26]
Nocturne G, Mariette X. Sjögren Syndrome-associated lymphomas: an update on pathogenesis and management [J]. Br J Haematol, 2015, 168(3): 317-327.
[27]
Nonaka KIK, Arai S, Nakao M, et al. A case of gastric mucosa-associated lymphoid tissue lymphoma in which magnified endoscopy with narrow band imaging was useful in the diagnosis[J]. World J Gastrointest Endosc, 2012, 16(4): 151-156.
[28]
Nakagawa S, Shimoyama T, Nakamura M, et al. The Resolution of Helicobacter suis-associated Gastric Lesions after Eradication Therapy [J]. Intern Med, 2018, 57(2): 203-207.
[29]
Park HS, Kim YJ, Yang WI, et al. Treatment outcome of localized Helicobacter pylori-negative low-grade gastric MALT lymphoma [J]. World J Gastroenterol, 2010, 16(17): 2158-2162.
[30]
Ryu KD, Kim GH, Park SO, et al. Treatment outcome for gastric mucosa-associated lymphoid tissue lymphoma according to Helicobacter pylori infection status: a single-center experience [J]. Gut Liver, 2014, 8(4): 408-414.
[31]
Gong EJ, Ahn JY, Jung HY, et al. Helicobacter pylori Eradication Therapy Is Effective as the Initial Treatment for Patients with H. pylori-Negative and Disseminated Gastric Mucosa-Associated Lymphoid Tissue Lymphoma [J]. Gut Liver, 2016, 10(5): 706-713.
[32]
Kim JS, Kang SH, Moon HS, et al. Clinical Outcome of Eradication Therapy for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma according to H. pylori Infection Status [J]. Gastroenterol Res Pract, 2016, 2016: 6794848.
[33]
柳娟, 杜凌, 陈刚. 根除幽门螺杆菌对胃黏膜相关淋巴组织淋巴瘤疗效分析[J]. 临床消化病杂志, 2017, 29(3): 129-131.
[34]
邵龙飞, 许周毅, 梁佳毅, 等. 幽门螺杆菌感染与胃MALT淋巴瘤免疫微环境的影响及意义 [J]. 临床与实验病理学杂志, 2023, 39(6): 650-654.
[35]
Rahman SH, Chaudhry AW, Raoof S, et al. Helicobacter pylori-Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Presenting as Massive Gastrointestinal Bleed [J]. Cureus, 2022, 14(9): e29125.
[36]
Kim SH, Soliman Y, Chitnavis VN, et al. Helicobacter Pylori-Negative MALT Lymphoma: A Series of Two Cases Presenting with Life-Threatening Upper Gastrointestinal Bleeding [J]. Case Rep Gastrointest Med, 2023, 2023: 8244696.
[37]
Lu SN, Huang C, Li LL, et al. Synchronous early gastric and intestinal mucosa-associated lymphoid tissue lymphoma in a Helicobacter pylori-negative patient: A case report [J]. World J Clin Cases, 2022, 10(33): 12447-12454.
[38]
Takigawa H, Yuge R, Masaki S, et al. Involvement of non-Helicobacter pylori helicobacter infections in Helicobacter pylori-negative gastric MALT lymphoma pathogenesis and efficacy of eradication therapy [J]. Gastric Cancer, 2021, 24(4): 937-945.
[39]
Moleiro J, Ferreira S, Lage P, et al. Gastric malt lymphoma: Analysis of a series of consecutive patients over 20 years [J]. UEG journal, 2016, 4(3): 395-402.
[40]
Li XW, Wang X, Zhan Z, et al. Evaluation of the clinical characteristics, management, and prognosis of 103 patients with gastric mucosa-associated lymphoid tissue lymphoma [J]. Oncol Lett, 2016, 11(3): 1713-1718.
[41]
Zullo Angelo, Ridola Lorenzo, De Francesco Vincenzo, et al. Eradication therapy in Helicobacter pylori-negative, gastric low-grade mucosa-associated lymphoid tissue lymphoma patients: a systematic review [J]. J Clin Gastroenterol, 2013, 47(10): 824-827.
[42]
Takigawa H, Yuge R, Miyamoto R, et al. Comprehensive Analysis of Gene Expression Profiling to Explore Predictive Markers for Eradication Therapy Efficacy against Helicobacter pylori-Negative Gastric MALT Lymphoma [J]. Cancers(Basel), 2023, 15(4): 1206.
[43]
Stathis A, Chini C, Bertoni F, et al. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type[J]. Ann Onco, 2009, 20(6): 1086-1093.
[1] 李朝阳, 任文琦, 侯令密, 蒋燕清, 刘沁豪, 赵永真, 张梅, 钱双强, 李金穗. T1-2N1miM0期乳腺癌患者乳房切除术后前哨淋巴结微转移的处理[J]. 中华乳腺病杂志(电子版), 2024, 18(02): 85-92.
[2] 蔡大明, 陆晓峰, 王行舟, 王萌, 刘颂, 夏雪峰, 沈晓菲, 杜峻峰, 管文贤. 三级淋巴结构在胃神经内分泌瘤中的预后价值及预后预测模型构建[J]. 中华普外科手术学杂志(电子版), 2024, 18(04): 401-405.
[3] 达热拜·热达提, 刘林, 赵为民, 孟涛, 雷程, 金博, 毕建军, 李新宇, 王海江. 中低位直肠癌新辅助放化疗后侧方淋巴结清扫术的临床观察[J]. 中华普外科手术学杂志(电子版), 2024, 18(04): 415-418.
[4] 李娇娇, 张军, 徐顺. 全程新辅助治疗联合全直肠系膜切除术对局部进展期直肠癌预后的影响研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(03): 283-286.
[5] 王东阳, 林琳, 娄熙彬. SII对局部进展期胃癌nCRT＋腹腔镜胃癌根治术后并发症及预后的影响研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(03): 315-318.
[6] 聂彬, 赵铁军, 于云宝, 李欢, 谢林峻. 单孔加一孔腹腔镜手术与传统腹腔镜手术治疗乙状结肠癌的疗效与分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(03): 330-333.
[7] 颜晓敏, 崔嵘嵘. 23例乳腺佩吉特病的经验交流[J]. 中华普外科手术学杂志(电子版), 2024, 18(03): 353-354.
[8] 刘政宏, 王凤力, 吉亚君, 高佳. 胃癌中ELK3蛋白的表达与临床病理特征和预后的关系研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(02): 155-159.
[9] 张琳, 李婷. CRIP1在胃癌中的表达及与临床病理指标和预后的关系研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(02): 171-175.
[10] 周慧宇, 吕定阳, 双卫兵. 联合系统性免疫炎症指数和预后营养指数预测腹腔镜肾切除术后肾癌患者的预后[J]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(03): 225-231.
[11] 朱显钟, 李金雨, 于忠英, 温路生. 淋巴结平均直径与无淋巴结转移肾癌病理特征及预后关系研究[J]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(02): 146-151.
[12] 曾谣, 谢琴, 陈显育, 王平根, 毛玲秋, 何丹玲, 杜飞, 郑希彦, 何函樨. CDC42EP2基因与肝癌预后、免疫细胞浸润关系及其对细胞迁移侵袭的影响[J]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 363-369.
[13] 邹健, 从建华, 田玥, 黄旻坤, 孙婷, 王志勤, 沈俪骅, 高臻晖. 肺磨玻璃结节与幽门螺杆菌感染的相关性研究[J]. 中华消化病与影像杂志(电子版), 2024, 14(03): 258-262.
[14] 陈憩, 顾于蓓. 不同亚型上消化道克罗恩病的临床特点和预后差异研究[J]. 中华消化病与影像杂志(电子版), 2024, 14(02): 121-127.
[15] 朱菡, 卓士超, 吴迪, 朱雅楠, 韩佳欣. 术前血浆纤维蛋白原、血脂水平及MMR表达与结直肠癌病理特点及预后的相关性[J]. 中华消化病与影像杂志(电子版), 2024, 14(02): 141-145.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号